Journal of Clinical Oncology, Vol 16, 2371-2376, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen

M Colleoni, G Martinelli, F Beretta, C Marone, A Gallino, M Fontana, R Graffeo, G Zampino, T De Pas, G Cipolla, C Martinoni and A Goldhirsch
Division of Medical Oncology and Service of Cardiology, European Institute of Oncology, Milan, Italy. mcol@ieo.cilea.it

PURPOSE: Malignant pericardial effusion, although highly variable, is an uncommon complication of cancer. It is often associated with symptoms like dyspnea, chest pain, and cough, which may be severe and disabling. We analyzed the results of our current treatment policy to evaluate the effectiveness and tolerance of a new approach for this disorder. PATIENTS AND METHODS: Patients with malignant pericardial effusions were treated with intracavitary thiotepa (15 mg on days 1, 3, and 5) through an indwelling pericardial cannula after extraction of as much pericardial fluid as possible on day 0. Responses were assessed by clinical examination, computed tomographic (CT) scan, and echocardiography before treatment, 1 month after treatment, and every 2 months thereafter. Twenty-three patients with malignant symptomatic pericardial effusion were treated and all were assessable for effectiveness and tolerance of the procedure. RESULTS: Nine patients with breast cancer, 11 with lung cancer, two with an unknown primary tumor, and one with metastatic melanoma were treated. In all but three patients, systemic medical treatment was started after completion of intracavitary therapy. Nineteen patients responded to treatment (83%; 95% confidence interval, 61% to 95%) with a rapid improvement of symptoms. The median time to pericardial effusion progression was 8.9 months (range, 1 to 26). No significant side effects were registered, except one patient who had transient grade III thrombocytopenia and leukopenia and one patient who had grade I leukopenia. CONCLUSION: A short course of intracavitary treatment with thiotepa is highly effective and well tolerated in the treatment of malignant pericardial effusion.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Task Force members, B. Maisch, P. M. Seferovic, A. D. Ristic, R. Erbel, R. Rienmuller, Y. Adler, W. Z. Tomkowski, G. Thiene, M. H. Yacoub, et al. Guidelines on the Diagnosis and Management of Pericardial Diseases Executive Summary: The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology Eur. Heart J., April 1, 2004; 25(7): 587 - 610. [Full Text] [PDF]

				K. Reynen, U. Kockeritz, and R. H. Strasser Metastases to the heart Ann. Onc., March 1, 2004; 15(3): 375 - 381. [Full Text] [PDF]

				B. Maisch and A. D Ristic Practical aspects of the management of pericardial disease Heart, September 1, 2003; 89(9): 1096 - 1103. [Full Text] [PDF]

				B. Maisch, A.D. Ristic, S. Pankuweit, A. Neubauer, and R. Moll Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin Eur. Heart J., October 2, 2002; 23(20): 1625 - 1631. [Abstract] [Full Text] [PDF]